Measuring the unknown: Calculating community viral load among HIV-infected MSM unaware of their HIV status in San Francisco from national HIV behavioral surveillance, 2004-2011

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 2, 2013, Pages

  Das, Moupali ^a,b   Raymond, H F ^a   Chu, Priscilla ^a   Nieves Rivera, Israel ^a   Pandori, Mark ^a,c   Louie, Brian ^a   Rauch, Leah ^a   Scheer, Susan ^a   Vittinghoff, Eric ^d   McFarland, Willi ^a,d  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b Divisions of HIV AIDS and Infectious Disease   (United States)

^c Department of Laboratory Medicine ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; HEALTH SURVEY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MEN WHO HAVE SEX WITH MEN; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; ATTITUDE TO HEALTH; BLOOD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MALE HOMOSEXUALITY; SEXUAL BEHAVIOR; UNITED STATES;

VIRUS RNA;

HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; RNA, VIRAL; SAN FRANCISCO; SEXUAL BEHAVIOR; UNITED STATES; VIRAL LOAD;

EID: 84879769894     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828ed2e4     Document Type: Letter

References (12)

1. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5:e11068.
2. Castel AD, Befus M, Willis S, et al. Use of the community viral load as a population-based bio-marker of HIV burden. AIDS. 2012;26:345-353.
3. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532-539.
4. Geng EH, Hare CB, Kahn JO, et al. The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/mL in a public health setting. Clin Infect Dis. 2012;55:1690-1697.
5. Jain V, Liegler T, Kabami J, et al. Assessment of population-based HIV RNA levels in a rural East African setting using a finger prick-based blood collection method. Clin Infect Dis. 2013;56:598-605.
6. Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
7. Smith MK, Powers KA, Muessig KE, et al. HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med. 2012;9:e1001260.
8. Cohen MS, Dye C, Fraser C, et al. HIV treatment as prevention: debate and commentary- will early infection compromise treatment-as-pre-vention strategies? PLoS Med. 2012;9:e1001232.
9. Raymond HF, Chen YH, Ick T, et al. A new trend in the HIV epidemic among men who have sex with men, San Francisco, 2004-2011. J Acquir Immune Defic Syndr. 2013;62:584-589.
10. Walker BD. Elite control of HIV infection: implications for vaccines and treatment. Top HIV Med. 2007;15:134-136.
11. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early anti-retroviral therapy. N Engl J Med. 2011;365: 493-505.
12. Granich R, Gupta S, Suthar AB, et al. Antire-troviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011;9:446-469.